Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sam Slutsky
LIFE
Sam Slutsky
LifeSci Capital
Wall Street Analyst
★★★★☆
#295
on 13Foresight · ranked by our own returns
59%
Success Rate
+23.3%
Average Return
13 of 22 calls profitable · +21.7% vs benchmark
📈 Across the calls we could measure, roughly 59% of Sam Slutsky's ratings turned a profit when each position was held for 1 year — averaging +23.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

232 Buy 18 Hold 0 Sell
Sam's Stock Coverage 21 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ABVX
Abivax SA Sponsored ADR
 Jun 16, 2026 BUY Strong Buy
+20.4% avg upside
15 analysts
$170.00
72.40% Upside
 ·
CLDX
Celldex
 Jun 15, 2026 BUY Strong Buy
+18.8% avg upside
28 analysts
$67.00
104.92% Upside
 +0.8%
SYRE
Spyre Therapeutics
 Jun 15, 2026 BUY Strong Buy
-14.3% avg upside
23 analysts
$103.00
18.86% Upside
 +0.0%
ELVN
Enliven Therapeutics
 Jun 11, 2026 BUY Strong Buy
+7.6% avg upside
14 analysts
$60.00
33.46% Upside
 +7.7%
OLMA
Olema Pharmaceuticals
 Jun 06, 2026 BUY Strong Buy
+309.3% avg upside
16 analysts
$24.00
160.30% Upside
 -7.7%
ORKA
Oruka Therapeutics
 May 23, 2026 BUY Strong Buy
+62.9% avg upside
16 analysts
$125.00
71.80% Upside
 +18.3%
PYXS
Pyxis Oncology
 May 23, 2026 BUY Strong Buy
+255.0% avg upside
13 analysts
$6.00
199.97% Upside
 +16.6%
IMVT
Immunovant
 May 23, 2026 BUY Strong Buy
+11.1% avg upside
24 analysts
$45.00
29.62% Upside
 +2.6%
DMRA
Damora Therapeutics
 May 16, 2026 BUY Strong Buy
+26.5% avg upside
19 analysts
$45.00
107.50% Upside
 ·
IMUX
Immunic
 May 16, 2026 BUY Strong Buy
+166.9% avg upside
21 analysts
$56.00
297.70% Upside
 +18.9%
ALXO
ALX Oncology Holdings
 May 16, 2026 HOLD Strong Buy
+1138.7% avg upside
11 analysts
 — -27.5%
CGON
CG Oncology, Inc.
 May 16, 2026 BUY Strong Buy
+42.0% avg upside
17 analysts
$108.00
77.31% Upside
 -5.6%
AVBP
ArriVent BioPharma, Inc.
 May 16, 2026 BUY Strong Buy
+38.0% avg upside
15 analysts
$42.00
32.99% Upside
 +16.0%
TSE:EPRX
Eupraxia Pharmaceuticals
 May 15, 2026 BUY Strong Buy
+150.4% avg upside
8 analysts
$22.37
148.71% Upside
 ·
TCRX
TScan Therapeutics
 May 09, 2026 BUY Strong Buy
+836.7% avg upside
12 analysts
$6.00
549.63% Upside
 -23.7%
OKUR
OnKure Therapeutics
 May 09, 2026 BUY Buy
+453.1% avg upside
12 analysts
$16.00
277.28% Upside
 -10.5%
COGT
Cogent Biosciences
 May 09, 2026 BUY Strong Buy
+9.2% avg upside
26 analysts
$55.00
60.67% Upside
 +0.4%
PVLA
Palvella Therapeutics
 May 09, 2026 BUY Strong Buy
+46.0% avg upside
27 analysts
$225.00
100.85% Upside
 -7.4%
IFRX
InflaRx
 Apr 29, 2026 HOLD Buy
+391.6% avg upside
11 analysts
 — +20.2%
DBVT
DBV Technologies SA - American
 Apr 20, 2026 BUY Strong Buy
+49.4% avg upside
15 analysts
$46.00
187.47% Upside
 -17.1%
GYRE
Gyre Therapeutics
 Dec 27, 2022 BUY Strong Buy
+218.8% avg upside
15 analysts
$7.50
22.59% Upside
 +456.2%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sam Slutsky — Frequently Asked Questions
How accurate are Sam Slutsky's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Sam's ratings were profitable over a one-year hold, with an average return of +23.1% per rating, or +21.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sam ranked on 13Foresight?
Sam Slutsky is currently ranked #295 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sam cover?
Sam most recently has ratings on ABVX, CLDX, SYRE, ELVN, OLMA, ORKA, PYXS, IMVT, DMRA, IMUX, ALXO, CGON and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.